Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 272

1.

Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.

Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG.

Ann Intern Med. 2007 Jan 2;146(1):25-33. Review.

PMID:
17200219
2.

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.

Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.

Am J Hematol. 2005 Apr;78(4):275-80.

3.
4.

Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review.

Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN.

Ann Intern Med. 2004 Jan 20;140(2):112-20. Review.

PMID:
14734334
5.

Rituximab for children with immune thrombocytopenia: a systematic review.

Liang Y, Zhang L, Gao J, Hu D, Ai Y.

PLoS One. 2012;7(5):e36698. doi: 10.1371/journal.pone.0036698. Epub 2012 May 30. Review.

6.

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.

Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB.

Br J Haematol. 2004 Apr;125(2):232-9.

PMID:
15059147
7.

Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.

Koulova L, Alexandrescu D, Dutcher JP, O'Boyle KP, Eapen S, Wiernik PH.

Am J Hematol. 2005 Jan;78(1):49-54.

8.

Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.

Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, Kentos A, Pierre P, Boulet D, Bries G, Lê PQ, Janssens A, Delannoy A.

J Intern Med. 2009 Nov;266(5):484-91. doi: 10.1111/j.1365-2796.2009.02126.x. Epub 2009 Apr 27.

9.

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.

Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, Vekhoff A, Chauveheid MP, Stirnemann J, Galicier L, Bourgeois E, Haiat S, Varet B, Leporrier M, Papo T, Khellaf M, Michel M, Bierling P.

Blood. 2008 Aug 15;112(4):999-1004. doi: 10.1182/blood-2008-01-131029. Epub 2008 May 7.

10.

Rituximab treatment for symptomatic chronic ITP.

Tamminga RY, Bruin MC.

Pediatr Blood Cancer. 2006 Oct 15;47(5 Suppl):714-6. Review.

PMID:
16933264
11.

Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.

Zhou Z, Yang R.

Crit Rev Oncol Hematol. 2008 Jan;65(1):21-31. Epub 2007 Jul 30. Review.

PMID:
17681784
12.

Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.

Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR; Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP.

Ann Hematol. 2006 Jun;85(6):400-6. Epub 2006 Mar 21. Erratum in: Ann Hematol. 2006 Aug;85(8):558. Dosage error in article text.

PMID:
16550390
13.

[Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].

Wang W, Yu QH, Zhang HY, Chu XX, Chen F, Zhang CQ, Zhou YH, Hou M.

Zhonghua Nei Ke Za Zhi. 2008 Mar;47(3):225-7. Chinese.

PMID:
18785508
14.

First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.

Rodeghiero F.

Eur J Haematol Suppl. 2008 Feb;(69):19-26. doi: 10.1111/j.1600-0609.2007.01000.x. Review.

PMID:
18211569
15.

Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP).

Alasfoor K, Alrasheed M, Alsayegh F, Mousa SA.

Ann Hematol. 2009 Mar;88(3):239-43. doi: 10.1007/s00277-008-0574-9. Epub 2008 Aug 15.

PMID:
18704420
16.

Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.

Schweizer C, Reu FJ, Ho AD, Hensel M.

Ann Hematol. 2007 Oct;86(10):711-7. Epub 2007 Jul 11.

PMID:
17622529
17.

Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?

Cooper N, Evangelista ML, Amadori S, Stasi R.

Curr Opin Hematol. 2007 Nov;14(6):642-6. Review.

PMID:
17898569
18.

Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.

Latifzadeh SZ, Entezari V.

Clin Appl Thromb Hemost. 2006 Oct;12(4):489-92.

PMID:
17000895
19.

Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.

Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, Marin L, Cavallin M, Bocchia M, Defina M, Ippoliti M, Ferrara F, Patriarca F, Avanzini MA, Regazzi M, Baccarani M, Isola M, Soldano F, Fanin R.

Haematologica. 2008 Jun;93(6):930-3. doi: 10.3324/haematol.12206. Epub 2008 Apr 9.

20.

Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study.

Giagounidis AA, Anhuf J, Schneider P, Germing U, Söhngen D, Quabeck K, Aul C.

Eur J Haematol. 2002 Aug;69(2):95-100.

PMID:
12366712

Supplemental Content

Support Center